Covid 19: DCGI permits marketing of Covishield, Covaxin at hospitals, clinics
New Delhi, January 27: The Central Drugs Standard Control Organisation (CDSCO) has now upgraded the permission for COVAXIN and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions confirms Union Health Minister Dr Mansukh Mandaviya.
Also Read | Coronavirus update: India reports 2.86 lakh Covid-19 cases in 24 hours
The Drugs Controller General of India (DCGI) on Thursday granted conditional market approval for Covishield and Covaxin. Earlier, reports had suggested that the DCGI is expected to give the regular market approval to Covishield and Covaxin vaccine after the price fixation. Quoting official sources stated that the price of Covishield and Covaxin is likely to be capped at Rs 275 per dose plus an additional service charge of Rs 150.
According to them, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable. As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorized for emergency use in the country.
A Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organization on January 19 recommended granting regular market approval to Covid vaccines Covishield and Covaxin for use in the adult population subject to certain conditions
Also Read |No side-effect of Covid vaccine on fertility, pregnancy, claims study
The vaccines will not be available in medical stores. The hospitals and clinics can purchase the vaccines. Vaccination data has to be submitted to DCGI every six months. Data is to be updated on CoWIN app also.
-PTC News
